Human EpCAM targeted genetically engineered lymphocyte, preparation method and use thereof

A lymphocyte and gene technology, applied in the field of genetic engineering, can solve the problem of no effective chimeric antigen receptor report and so on

Active Publication Date: 2018-01-19
WEST VAC BIOPHARMA CO LTD
View PDF2 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There is no effective chimeric anti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human EpCAM targeted genetically engineered lymphocyte, preparation method and use thereof
  • Human EpCAM targeted genetically engineered lymphocyte, preparation method and use thereof
  • Human EpCAM targeted genetically engineered lymphocyte, preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Obtaining the full-length CAR gene and completing the construction of the recombinant plasmid vector

[0068] 1. Synthesize primers to obtain (ScFv-V)-(CD8α)-(CD28)-(4-1BB)-(CD3-z) fusion fragment by overlapping PCR method.

[0069] 2. Obtain the full-length CAR gene by overlapping PCR.

[0070] The specific plan is as follows:

[0071] a) Use primers F1 and R1 to amplify the coding gene of ScFv-E segment, and use F2 and R2 to amplify the coding gene of (CD8α)-(CD28)-(4-1BB)-(CD3-z). Among them, the gene codes of ScFv-E, (CD8α)-(CD28)-(4-1BB)-(CD3-z) were all obtained by chemical synthesis (synthesized by Guangzhou Funeng Gene Co., Ltd.).

[0072] b) Using ScFv-E and (CD8α)-(CD28)-(4-1BB)-(CD3-z) as templates and F1 and R2 as primers, the full-length CAR gene was obtained by PCR.

[0073] Primers (5' to 3') used to obtain the CAR gene:

[0074] F1 (SEQ ID NO: 12):

[0075] 5'-GCtctagaATGTACAGGATGCAACTCCTGTCTTGC-3';

[0076] R1 (SEQ ID NO: 13):

[0077] ...

Embodiment 2

[0084] Example 2 Transfection of Lymphocytes, Expression Detection

[0085] 1. Virus transfection of lymphocytes and detection of target gene expression.

[0086] Put the chimeric antigen receptor gene prepared in Example 1 into the lentiviral vector CD510B-1-pCDH, and co-transfect 293T cells (purchased from ATCC cell bank) with the other two auxiliary vectors psPAX2 and pMD2.G , packaged to obtain virus particles, and obtain high-titer lentiviral vectors after centrifugation and concentration. After T lymphocytes were isolated from human peripheral blood by density gradient centrifugation, the lymphocytes were stimulated with CD3 antibody (lug / ml) and IL-2 (300IU / ml). Two days later, the lymphocytes were collected for virus transfection, and the lymphocytes were cultured for 48 hours. The transfected lymphocytes were collected, and the total protein of the cells was extracted for western blotting. The results showed that CAR was highly expressed in transfected T lymphocytes...

Embodiment 3

[0089] Example 3 Killing effect on tumor cells expressing EpCAM

[0090] To investigate the killing effect of CAR genetically engineered T cells that can specifically recognize EpCAM on tumor cells. use 51 Cr release assay to detect the targeted killing effect of genetically engineered T cells dependent on the expression level of EpCAM.

[0091] Implementation process: Target cells Hela, MDA-MB 231 and SW480 with different EpCAM expression levels were labeled with sodium chromate and seeded into 96-well plates. At the same time, T cells infected with EpCAM CAR virus (EpCAM CAR-T) cells were used as effector cells, and the EpCAM CAR-T cells were added to the 96-well plate by counting at the effect-to-target ratio of 10:1, 5:1 and 2.5:1. , and incubated with target cells. At the same time, T cells not infected with EpCAM CAR virus (No CAR-T) were used as a control, counted at the same effect-to-target ratio, and added to a 96-well plate to incubate with target cells. Three s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the genetic engineering field, in particular to a human EpCAM targeted genetically engineered lymphocyte, a preparation method and use thereof. Technically, the invention aimsto provide a new effective means for immunotherapy of tumors. The technical scheme for solving the technical problem of the invention firstly provides a single-chain antibody capable of recognizing human EpCAM, a chimeric antigen receptor (CAR) containing the single-chain antibody, a vector carrying the chimeric antigen receptor, and a lymphocyte modified by the chimeric antigen receptor. After specific recognition of EpCAM overexpressed tumor cells, the EpCAM targeted chimeric antigen receptor modified lymphocyte provided by the invention can play an anti-tumor role through cytokine releaseand cytotoxicity, and can remarkably tumor formation, tumor growth and lung metastasis in vivo, thus having good application prospect.

Description

technical field [0001] The invention relates to the field of genetic engineering, in particular to a genetically engineered lymphocyte targeting human EpCAM, a preparation method and application thereof. Background technique [0002] In the process of cellular immunity, T lymphocytes play a major role. Cellular immunity mediated by T cells is mainly through T cell receptor (T cell receptor, TCR) specific recognition of antigenic peptides displayed by the major histocompatibility complex (MHC) on the cell surface, thereby activating T cell intracellular signaling , to specifically kill the target cells. This plays a vital role in timely removal of diseased cells in the body and prevention of tumors. [0003] Tumors can evade the surveillance of the immune system through various ways to produce immune escape, so that tumor cells can survive in the body and tumors occur. However, in tumor patients, there are still a small number of immune cells that can recognize and kill tu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K19/00C12N15/13C12N15/62C12N15/867C12N5/10A61K35/17A61K38/17A61K47/68A61P35/00
Inventor 魏于全王永生王玮张炳兰郭福春
Owner WEST VAC BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap